MedTrace Logo

ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis

NCT05725213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2024-02-23

No results posted yet for this study

Summary

The objective of this non-interventional study (NIS) is to gain comprehensive insights into the practicability of ADL-PDT with Metvix® in patients with actinic keratoses under real-world conditions.

Conditions

  • Actinic Keratoses

Interventions

DRUG

Metvix® 160 mg/g Creme

Patients are treated with Metvix creme and exposed to artificial daylight

Sponsors & Collaborators

  • Galderma Laboratorium GmbH

    lead INDUSTRY

Principal Investigators

  • Rolf-Markus Szeimies, Prof. Dr. · KLINIKUM VEST GMBH - Knappschaftskrankenhaus Recklinghausen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-10-30
Completion
2023-10-30
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725213 on ClinicalTrials.gov